KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Krystal Biotech, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026

$320.25+3.67 (+1.16%)

Close on Oct 19, 2026

Community

Notes and questions about Krystal Biotech from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Krystal Biotech's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is KRYS.

Revenue growth22.6% · median 34.5%

Operating margin44.9% · median -5.2%

Net margin54.8% · median -4.2%

Advertisement
300 × 250